To decrease the impact of COVID-19, and related hospitalisations and mortality, countries should plan for a continued roll-out of COVID vaccines in 2023.
This document offers an overview of the available scientific evidence and epidemiological situation and provides public health considerations to support discussions and decisions on the planning and implementation of COVID-19 vaccination campaigns for 2023.
This update reports on one of the ECDC multi-country studies that is centred around the hospital setting and severe disease, with the aim of assessing vaccine effectiveness against severe acuterespiratory infection (SARI) due to laboratory-confirmed SARS-CoV-2 within the ECDC VaccineEffectiveness, Burden and Impact Studies infrastructure (VEBIS) [1,2].
Resistance of Salmonella and Campylobacter to commonly used antimicrobials is frequently observed in humans and animals, reveals a report by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
This report provides an overview of the main findings of the 2020–2021 harmonised AMR monitoring in Salmonella spp., Campylobacter jejuni and C. coli in humans and food-producing animals and relevant meat thereof.
This report provides an updated overview on the progress of national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on overall vaccine uptake and uptake by target group and vaccination strategies and policies.